Ose immunotherapeutics Headquarters & Office Locations

Ose immunotherapeutics (Frankfurt Stock Exchange (FSX): 6OP) is headquartered in Nantes, Loire-Atlantique, France. Founded in 2012, the company operates across 1 countries with approximately 64 employees worldwide.

Where is Ose immunotherapeutics's main office?

Ose immunotherapeutics's main headquarters office is located at 22 Boulevard Bénoni Goullin, Nantes, Loire-Atlantique 44200. This serves as the company's primary corporate address and is home to its executive leadership team.

Ose immunotherapeutics regional offices

Beyond its headquarters in Nantes, Ose immunotherapeutics maintains 10 offices across 1 countries. Regional offices span 1 countries.

Ose immunotherapeutics contact information

The main switchboard for Ose immunotherapeutics headquarters can be reached at 33228291010. For investor relations, visit ose-immuno.com/investor-relations.

What does Ose immunotherapeutics do?

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.